These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27577234)

  • 1. BAY 81-8973 (Octocog Alfa; Kovaltry
    Keating GM
    BioDrugs; 2016 Oct; 30(5):453-459. PubMed ID: 27577234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials.
    Kenet G; Moulton T; Wicklund BM; Ahuja SP; Escobar M; Mahlangu J
    J Blood Med; 2023; 14():379-388. PubMed ID: 37309365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
    Yang R; Sun J; Zhao Y; Wang X; Wu D; Tseneklidou-Stoeter D; Wu J; Church N
    Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
    Oldenburg J; Windyga J; Hampton K; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
    Santagostino E; Kenet G; Fischer K; Biss T; Ahuja S; Steele M
    Haemophilia; 2020 May; 26(3):e55-e65. PubMed ID: 32212300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
    Kenet G; Ljung R; Rusen L; Kerlin BA; Blanchette V; Saulytė Trakymienė S; Uscatescu V; Beckmann H; Tseneklidou-Stoeter D; Church N
    Thromb Res; 2020 May; 189():96-101. PubMed ID: 32197139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
    Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
    Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII.
    Shah A; Delesen H; Garger S; Lalezari S
    Haemophilia; 2015 Nov; 21(6):766-71. PubMed ID: 25952661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.
    Fujii T; Hanabusa H; Shima M; Morinaga T; Fukutake K
    Int J Hematol; 2017 Mar; 105(3):280-286. PubMed ID: 27832514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.
    Mahlangu J; Lopez Fernandez MF; Santagostino E; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Church N
    Eur J Haematol; 2020 Jun; 104(6):594-601. PubMed ID: 32112434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
    Kavakli K; Yang R; Rusen L; Beckmann H; Tseneklidou-Stoeter D; Maas Enriquez M;
    J Thromb Haemost; 2015 Mar; 13(3):360-9. PubMed ID: 25546368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.
    Frampton JE; Wagstaff AJ
    Drugs; 2008; 68(6):839-53. PubMed ID: 18416588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.
    Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Tueckmantel C; Cabre-Marquez JF; Wang M
    Eur J Haematol; 2023 Jan; 110(1):77-87. PubMed ID: 36192847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lonoctocog Alfa: A Review in Haemophilia A.
    Al-Salama ZT; Scott LJ
    Drugs; 2017 Oct; 77(15):1677-1686. PubMed ID: 28900904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
    Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.